EODData

MEMBERSHIP REGISTER LOG IN

FRA, 2LB: Iovance Biotherapeutics Inc

22 Jan 2026
LAST:

2.114

CHANGE:
 0.06		OPEN:
2.114		HIGH:
2.114		ASK:
0.000		VOLUME:
1.7K
CHG(%):
3.05		PREV:
2.051		LOW:
2.114		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Jan 262.1142.1142.1142.1141.7K
21 Jan 262.0512.0512.0512.0511.7K
20 Jan 261.9391.9391.9391.9391.7K
19 Jan 261.9981.9981.9981.9981.7K
16 Jan 261.9261.9471.9261.9361.7K
15 Jan 262.0362.0361.9461.9462.1K
14 Jan 261.9782.0251.9782.025269
13 Jan 262.0322.0322.0322.0321.5K
12 Jan 262.1722.1722.1722.1721.5K
09 Jan 262.2252.2312.2252.2311.5K

PROFILE

Name:Iovance Biotherapeutics Inc
About:Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Sector:Healthcare
Industry:Biotechnology
Address:825 Industrial Road, San Carlos, CA, United States, 94070
Website:https://www.iovance.com
ISIN:US4622601007
LEI:549300220Z2GHH33XL82

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.82 
Forward P/E:-1.04 
PEG Ratio:-1.04 
Price to Sales:3.70 
Price to Book:1.51 
Profit Margin:-1.59 
Operating Margin:-1.33 
Return on Assets:-0.27 
Return on Equity:-0.54 
Revenue:212.74M 
Shares:361.85M 
Market Cap:764.78M 

TECHNICAL INDICATORS

MA5:2.015.3%
MA10:2.043.4%
MA20:2.130.9%
MA50:2.043.5%
MA100:1.967.6%
MA200:2.034.2%
STO9:75.35
STO14:45.66
RSI14:47.87
WPR14:-54.34
MTM14:-0.06
ROC14:-0.03 
ATR:0.08 
Week High:2.110.0%
Week Low:1.939.7%
Month High:2.4314.8%
Month Low:1.934.2%
Year High:6.01184.5%
Year Low:1.4249.2%